Replies to post #133661 on Biotech Values

[iwfal]

Humira is only one of six compounds in the collaboration.

Sure - but the biggest one (as you know). And yet at $200-300M to Momenta it is less than 1/2 the size of the likely Cop+Lov revenue stream to Momenta. So, to quote myself (since your pointing to Humira does nothing to change the calc)

Even with 6 of these generics, some with higher royalty and/or higher sales, the total will be, perhaps, $1.5B - in 10 years or so